TY - CHAP M1 - Book, Section TI - TTP, HUS, and Other Thrombotic Microangiopathies A1 - Long Zheng, X. A1 - Mangalmurti, Nilam A2 - Hall, Jesse B. A2 - Schmidt, Gregory A. A2 - Kress, John P. PY - 2015 T2 - Principles of Critical Care, 4e AB - Thrombotic microangiopathy (TMA), a pathologic term, describes a syndrome of microangiopathic hemolytic anemia (MAHA) and thrombocytopenia with various degrees of organ dysfunction.TMA includes thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndromes (HUS), as well as other related syndromes.TTP is primarily caused by hereditary or acquired deficiency of plasma ADAMTS13, whereas HUS is mainly caused by Shiga toxin–producing E coli and/or abnormalities of complement activation and regulation.TTP should be differentiated from HUS, disseminated intravascular coagulation (DIC), collagen vascular disease with vasculitis, and Hemolytic anemia, Elevated Liver enzymes, and Low Platelets) (HELLP) syndrome, etc.Plasma therapy remains the mainstay of therapy for TTP and atypical HUS (aHUS). However, the treatment for aHUS has been less satisfactory. Adjunctive therapies such as corticosteroids, immunosuppressive agents, and anti-CD20 monoclonal antibodies such as rituximab or anti-C5 monoclonal antibodies such as eculizumab may be considered for refractory TTP or HUS cases. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accesssurgery.mhmedical.com/content.aspx?aid=1107722755 ER -